Are you Dr. Boral?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 29 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Millennium Pharm.
40 Landsdowne St.
Cambridge, MA 02139Phone+1 617-444-1351- Is this information wrong?
Summary
- Dr. Anthony Boral, MD is an oncologist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1998
- Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
- Albert Einstein College of MedicineClass of 1993
Certifications & Licensure
- MA State Medical License 1995 - 2021
Publications & Presentations
PubMed
- 4 citationsPsychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.Brad Padilla, Alan L. Shields, Fiona Taylor, Xiaoran Li, Jeffrey G. McDonald, Tanya Green, Anthony L. Boral, Hui-Min Lin, Cem Akin, Frank Siebenhaar, Brenton G. Mar> ;Orphanet Journal of Rare Diseases. 2021 Oct 18
- 7 citationsDevelopment of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©.Fiona Taylor, Cem Akin, Roger E. Lamoureux, Brad Padilla, Tanya Green, Anthony L. Boral, Iyar Mazar, Brenton G. Mar, Alan L. Shields, Frank Siebenhaar> ;Orphanet Journal of Rare Diseases. 2021 Oct 9
- 5 citationsPsychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).Fiona Taylor, Xiaoran Li, Christine Yip, Brad Padilla, Brenton G. Mar, Tanya Green, Ronny G. Oren, Anthony L. Boral, Hui-Min Lin, Alan L. Shields, Jason Gotlib> ;Leukemia Research. 2021 May 1
- Join now to see all
Press Mentions
- Blueprint’s Tagrisso Combination Shows Early Promise in NSCLCSeptember 26th, 2018